Datasheet is currently unavailable. Try again or CONTACT US
Human IgM Fab mu
009-0109
009-0109-0001
2 mg
1 mg
Liquid (sterile filtered)
Liquid (sterile filtered)
SDS-PAGE
Human
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Human IgM Fab µ Fragment (BULK ORDER) - 009-0109
Human Myeloma Fragment, fab fragment of a human
Human
IgM
Native Protein
Target Details
HUMAN IgM (myeloma) Fab µ fragment was prepared from serum by a multi-step process which includes delipidation, selective precipitation, tandem molecular sieve chromatography and trypsin digestion followed by extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Human Serum. No reaction was observed against anti-Human IgG F(c). Some light chain cross reactivity will occur with anti-Human IgG.
Application Details
SDS-PAGE
Monovalent Fab fragments of affinity-purified, secondary antibodies are offered to cover (block) the surface of immunoglobulins for double labeling primary antibodies from the same host species, or to block endogenous immunoglobulins in tissue sections or on cell surfaces. They can be used for these purposes because each Fab fragment has only a single antigen binding site. HUMAN IgM (myeloma) Fab µ fragment has been tested in SDS-PAge and can be utilized as a control or standard reagent in Western Blotting and ELISA experiments. Specific conditions should be optimized by the user.
Formulation
2.0 mg/mL by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Wet Ice
Store vial at 4° C prior to opening. This product is stable 4° C as an undiluted liquid. Dilute only prior to immediate use. For extended storage mix with an equal volume of glycerol, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing.
Expiration date is one (1) year from date of receipt.
Human IgM Fab mu is ideal for investigators involved in serum protein component research. IgM is by far the physically largest antibody in the human circulatory system. It is the first antibody to appear in response to initial exposure to antigen. The spleen is the major site of specific IgM production. Distinct heavy chains differ in size and composition; alpha and gamma contain approximately 450 amino acids, while μ and ε have approximately 550 amino acids.
No test method can provide total assurance that the hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or any other infectious agents are absent. Thus, all blood products, including purified proteins derived from human blood sources, should be handled at Biosafety Level 2 as recommended by the CDC\NIH manual entitled Biosafety in Microbiological and Biomedical Laboratories for potentially infectious human serum, blood specimens or proteins derived from same. Source material for the human blood product supplied to your facility has been tested for the detection of HIV antibody, Hepatitis B surface antigen, antibody to Hepatitis C, HIV 1 antigen(s), antibody to HTLV - I/II, and syphilis by FDA guidelines. All units were found to be non-reactive/negative for these tests. All human blood source material is collected in FDA licensed centers and is tested with FDA approved test kits.; This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
